[HTML][HTML] Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities
Y Jiang, Y Chen, Q Yu, Y Shi - BioDrugs, 2023 - Springer
Psoriasis is a systemic immune-mediated disease associated with an increased risk of
comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome …
comorbidities, such as psoriatic arthritis, cardiovascular disease, metabolic syndrome …
Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis
SS Mattay, M Zamani, D Saturno, EV Loftus Jr… - Clinical …, 2023 - Elsevier
ABSTRACT Background and Aims Recent studies raise concern for increased risk of major
adverse cardiovascular events (MACE) with Janus kinase inhibitors (JAKi) used to treat …
adverse cardiovascular events (MACE) with Janus kinase inhibitors (JAKi) used to treat …
Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical …
Importance Psoriasis is an inflammatory condition associated with metabolic and
cardiovascular disease. Apremilast, a phosphodiesterase 4 inhibitor, is commonly used for …
cardiovascular disease. Apremilast, a phosphodiesterase 4 inhibitor, is commonly used for …
Comorbidities in psoriatic arthritis: a narrative review
A Panagiotopoulos, GE Fragoulis - Clinical Therapeutics, 2023 - Elsevier
Abstract Purpose Psoriatic arthritis (PsA) is a common type of inflammatory arthritis. Patients
with PsA present with certain extra-articular manifestations and comorbidities (often …
with PsA present with certain extra-articular manifestations and comorbidities (often …
[HTML][HTML] Apremilast long-term safety up to 5 years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Behçet's syndrome
PJ Mease, G Hatemi, M Paris, S Cheng, P Maes… - American journal of …, 2023 - Springer
Abstract Background Since US FDA approval in 2014, apremilast has consistently
demonstrated a favorable benefit–risk profile in 706,585 patients (557,379 patient-years of …
demonstrated a favorable benefit–risk profile in 706,585 patients (557,379 patient-years of …
Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study
O Fakih, M Desmarets, B Martin, C Prati… - …, 2023 - academic.oup.com
Objectives The objectives of this study were to describe the incidence of major adverse
cardiovascular events (MACEs) in French patients newly benefiting from the French Long …
cardiovascular events (MACEs) in French patients newly benefiting from the French Long …
Cardiovascular disease-associated skin conditions
L Hojman, C Karsulovic - Vascular Health and Risk Management, 2022 - Taylor & Francis
According to data from the American Heart Association and the World Health Organization,
cardiovascular disease (CVD) is the most frequent cause of premature death. Several …
cardiovascular disease (CVD) is the most frequent cause of premature death. Several …
[HTML][HTML] 2022 Taiwanese Dermatological Association (TDA), Taiwanese Association for Psoriasis and Skin Immunology (TAPSI), and Taiwan Society of cardiology …
Psoriatic disease is a chronic inflammatory disorder with skin and joint manifestations. Due
to the persistent inflammatory state exhibited by patients with psoriasis, multiple systemic …
to the persistent inflammatory state exhibited by patients with psoriasis, multiple systemic …
Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review …
NÁ Galajda, FA Meznerics, P Mátrai… - Journal of the …, 2024 - Wiley Online Library
Immune‐mediated inflammatory disease (IMID) patients including psoriasis, inflammatory
arthritides and bowel diseases have a higher risk of developing cardiovascular (CV) …
arthritides and bowel diseases have a higher risk of developing cardiovascular (CV) …
[HTML][HTML] Interleukin-17–targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile
R Queiro, E Aurrecoechea, S Alonso Castro… - Frontiers in …, 2023 - frontiersin.org
Spondyloarthritis is a group of immune-mediated rheumatic disorders that significantly
impact patients' physical function and quality of life. Patients with spondyloarthritis …
impact patients' physical function and quality of life. Patients with spondyloarthritis …